26 February 2025 Scandion Oncology CEO Francois Martelet, MD will take over CMO tasks Download Presentation Webcast Workbook
26 February 2025 Scandion Oncology’s Board of Directors emphasize need to find a partner before the Annual General Meeting Download Presentation Webcast Workbook
13 January 2025 Scandion Oncology announces final data from the CORIST trial and is ready to move into a randomized phase II Proof of Concept trial in Colorectal Cancer Download Presentation Webcast Workbook
20 November 2024 Warrants of series TO 2 were exercised to approximately 2.0 per cent and Scandion Oncology receives approximately SEK 0.3 million Download Presentation Webcast Workbook
14 November 2024 Last day of trading in warrants of series TO 2 in Scandion Oncology is today, 14 November 2024 Download Presentation Webcast Workbook
5 November 2024 Invitation to Scandion Oncology webcast and conference call November 11, 2024 Download Presentation Webcast Workbook
4 November 2024 Scandion Oncology announces the start of the exercise period for warrants of series TO 2 Download Presentation Webcast Workbook
31 October 2024 Correction: Scandion Oncology announces exercise price for warrants of series TO 2 Download Presentation Webcast Workbook
30 October 2024 Scandion Oncology announces exercise price for warrants of series TO 2 Download Presentation Webcast Workbook
19 August 2024 Scandion Oncology strengthens partnering outreach Download Presentation Webcast Workbook
16 August 2024 Scandion Oncology achieves Maximum Tolerated Dose for CORIST part 3 Download Presentation Webcast Workbook
11 July 2024 SCANDION ONCOLOGY’S RIGHTS ISSUE REGISTERED WITH THE DANISH BUSINESS AUTHORITY Download Presentation Webcast Workbook